Nxera Pharma Co (FRA:JSS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JSS Nxera Pharma Co Ltd FRA:JSS
72 GF Score
Price €4.88
GF Value €7.07
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:JSS
72GF Score
Nxera Pharma Co Ltd FRA:JSS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of €4.88 is trading 31% below its estimated GF Value™ of €7.07.

Key valuation signals for FRA:JSS:

  • Dividends Received:
  • GF Value™: €7.07 vs. price of €4.88 (31% below fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
72GF Score

Get the complete analysis for FRA:JSS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.88
Price
€7.07
GF Value